{"id":"p2y12-receptor-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2Y12 receptor antagonists prevent platelet activation by blocking the binding of adenosine diphosphate (ADP) to the P2Y12 receptor, a key step in platelet aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent thrombotic complications in cardiovascular disease. These agents are commonly used in acute coronary syndromes and after percutaneous coronary intervention.","oneSentence":"Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:35.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Prevention of thrombotic events after percutaneous coronary intervention"},{"name":"Secondary prevention of cardiovascular events"}]},"trialDetails":[{"nctId":"NCT07496281","phase":"PHASE4","title":"OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2027-03-01","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent","enrollment":2},{"nctId":"NCT04957719","phase":"PHASE3","title":"Selatogrel Outcome Study in Suspected Acute Myocardial Infarction","status":"ENROLLING_BY_INVITATION","sponsor":"Viatris Innovation GmbH","startDate":"2021-08-14","conditions":"Acute Myocardial Infarction","enrollment":14000},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07133191","phase":"PHASE1","title":"A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2025-10-07","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT03384966","phase":"PHASE2","title":"A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Stable Coronary Artery Disease","enrollment":346},{"nctId":"NCT03487445","phase":"PHASE2","title":"A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-07-10","conditions":"Acute Myocardial Infarction","enrollment":48},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT03447379","phase":"NA","title":"Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2017-12-15","conditions":"Coronary Artery Disease","enrollment":1452},{"nctId":"NCT02777580","phase":"PHASE4","title":"STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2017-08-01","conditions":"Myocardial Infarction","enrollment":609},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02619760","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":3045},{"nctId":"NCT03462498","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2018-04-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":3008},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT05162131","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers","status":"TERMINATED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2021-12-25","conditions":"Healthy","enrollment":34},{"nctId":"NCT04981041","phase":"PHASE4","title":"Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-12-16","conditions":"Acute Coronary Syndrome, Atrial Fibrillation","enrollment":2334},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT05307718","phase":"","title":"Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction","status":"UNKNOWN","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-12-15","conditions":"Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs","enrollment":1200},{"nctId":"NCT05166538","phase":"PHASE4","title":"Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-02-01","conditions":"Multi Vessel Coronary Artery Disease","enrollment":204},{"nctId":"NCT04999293","phase":"","title":"Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-07-20","conditions":"Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged","enrollment":1505},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT03362788","phase":"","title":"The Greek AntiPlatElet Atrial Fibrillation Registry.","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2017-12-01","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":654},{"nctId":"NCT04630288","phase":"","title":"Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2019-07-02","conditions":"Acute Coronary Syndromes","enrollment":1900},{"nctId":"NCT04369534","phase":"PHASE4","title":"Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University of Zagreb","startDate":"2015-12-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI","enrollment":120},{"nctId":"NCT02079194","phase":"NA","title":"Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-03-18","conditions":"Coronary Artery Disease","enrollment":3000},{"nctId":"NCT02407314","phase":"PHASE4","title":"Ticagrelor and Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Arkansas Heart Hospital","startDate":"2015-06","conditions":"Peripheral Arterial Disease","enrollment":26},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT02943369","phase":"PHASE4","title":"Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2017-07-28","conditions":"STEMI","enrollment":30},{"nctId":"NCT02227368","phase":"PHASE2","title":"Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-10-20","conditions":"Peripheral Artery Disease (PAD)","enrollment":40},{"nctId":"NCT03078257","phase":"PHASE1","title":"Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-01-01","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT02762864","phase":"NA","title":"Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-05","conditions":"Peripheral Artery Disease","enrollment":200},{"nctId":"NCT02402491","phase":"PHASE4","title":"Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-01","conditions":"Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT01226602","phase":"PHASE1","title":"Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"Blood Flow Speed, Coronary Flow Velocity","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":272,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"P2Y12 Receptor Antagonist","genericName":"P2Y12 Receptor Antagonist","companyName":"Fu Wai Hospital, Beijing, China","companyId":"fu-wai-hospital-beijing-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}